Susquehanna Fundamental Investments, LLC Protalix Bio Therapeutics, Inc. Call Options Transaction History
Susquehanna Fundamental Investments, LLC
- $4.33 Trillion
- Q2 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
Others Institutions Holding PLX
# of Institutions
70Shares Held
5.61MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$811,1600.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$804,6000.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$461,9580.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$423,2130.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$401,2440.03% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $49.8M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...